Back to search results

COQ10 and Vitamin E for Radiation Side Effects in Pelvic Cancers

This study is looking at whether taking Coenzyme Q10 (CoQ10) and Vitamin E daily for three months can help reduce the long-term side effects of radiation therapy for prostate, uterine, cervical, or anal cancer. Researchers want to know if these vitamins are safe and tolerable at high doses, and if they can lessen the severity of radiation-related problems. The study also aims to see if these vitamins improve your quality of life. You may be able to join if you are at least 19 years old, have one of these cancers, and are scheduled for radiation therapy. The study is currently unclear on its recruitment status.

Study design
This is an interventional study planning to enroll 200 participants. It will test Coenzyme Q10 and Vitamin E together.
What's involved
You would take Coenzyme Q10 and Vitamin E daily for 3 months. The study will measure side effects at 3-6 months and again at 2-3 years.
Compensation
Not stated in the trial record.
Follow-up
The study will measure radiation-associated toxicity for 2 to 3 years after treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07668284

COQ10 and Vitamin E for Off-Target Radiation Toxicity

Not Yet Recruiting
PHASE1Ages 19+InterventionalSupportive care
University of Nebraska
~200 participants
Updated 2026-06-25 on ClinicalTrials.gov
What's tested:Coenzyme Q10 Cap/TabVitamin E Cap/Tab

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Recommended Phase 2 Dose
Measured over 3-6 months
+1 more outcome measured

Conditions

Prostate Cancer
Uterine Cancer
Cervical Cancer
Anal Cancer

Explore related trials

Anal CarcinomaCervical CarcinomaMalignant Uterine NeoplasmProstate Carcinoma

Where it's being run

1 sites across 1 states
Nebraska1

Study leadership

  • Chi P Lin, MD · PRINCIPAL_INVESTIGATOR · University of Nebraska

Who to contact

Erin M Drengler, MS
[email protected]
1 402 552 2435
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Absolute Neutrophil Count (ANC) ≥ 500/mm3
Platelets ≥ 50,000/mm3 • Hemoglobin ≥ 8.0 g/dL. The use of transfusion or other intervention to achieve Hgb ≥ 8.0 g/dL is acceptable.
Calculated creatinine clearance (CrCl (mL/min); Cockcroft-Gault formula) ≥ 30 mL/min.
Total bilirubin ≤ 1.5X institutional upper limit of normal (ULN) or ≤3 X ULN for patients with known Gilbert's syndrome
AST (SGOT) and ALT (SGPT) ≤ 3X institutional ULN
PT/INR and PTT (in the absence of lupus anticoagulant) ≤ 2X institutional ULN.

What this trial measures

  • Recommended Phase 2 Dose3-6 months

    Determine if the initial dose of each vitamin is recommended for the remainder of study participants.

  • Incidence of Grade ≥2 (CTCAE) Radiation-Associated Toxicity2-3 years

    The incidence of CTCAE Grade ≥2 radiation therapy-associated toxicity occurring from completion of RT through 3 months post-RT